Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;30(5):508-518.
doi: 10.1016/j.jsps.2022.03.002. Epub 2022 Mar 10.

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review

Lina Kamal  1 , Ahmed Ramadan  1   2 , Suha Farraj  1   3 , Lydia Bahig  1 , Sameera Ezzat  1   4
Affiliations

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review

Lina Kamal et al. Saudi Pharm J. 2022 May.

Abstract

Background: Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the virus spread, disease burden, hospitalization, and mortality. Until mid of 2021, the NIH treatment guideline declared no single oral therapy was proven to treat mild to moderate cases. A new hope arose when a repurposed direct acting oral anti-viral agent "Molnupiravir" was shown to be effective in decreasing mortality and need for hospitalization in mild to moderate cases with relatively good safety profile; exhibiting a significant reduction in virus titers only after two days from administration. Molnupiravir recently granted the FDA emergency use authorization to treat mild to moderate COVID-19 patients with at least one risk factor for progression.

Methods: We performed a computer-based literature search of (PubMed, Science direct, MedRxiv, BioRxiv, ClinicalTrials.gov, ISRCTN, Cochrane COVID study register, EU registry, and CTRI registry) till February 15th, 2022. The following keywords were used in our search ("Molnupiravir", "NHC", "EIDD-2807", "MK-4482" or "EIDD-1931").

Results: We identified from the initial search a total of 279 articles; 246 articles (BioRxiv and MedRxiv N = 186, PubMed N = 33, Science direct N = 27) and 33 Clinical trials from the following registries (ISCTRN (N = 1), Clinical Trials.gov (N = 6), CTRI (N = 12), Cochrane (N = 14)). Through screening phases, 21 records were removed as duplicates and 198 irrelevant records were also excluded. The included studies in this systematic review were (N = 60) included 39 published papers and 21 clinical trials. After Manual addition (N = 4), the qualitative assessment included (N = 64).

Conclusion: Based on the cumulative evidence from preclinical and clinical studies, Molnupiravir is proven to be a well tolerated, direct acting oral anti-viral agent to halt the disease progression in mild to moderate COVID-19 cases; in terms of mortality and hospitalization rates.

Keywords: COVID-19; EIDD-1931; EIDD-2807; MK-4482; Molnupiravir; NHC; Repurposing anti-viral drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Prisma flowchart of the systematic review.
See this image and copyright information in PMC

References

    1. Abdelnabi R., Foo C.S., De Jonghe S., Maes P., Weynand B., Neyts J. Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model. J. Infect. Dis. 2021 doi: 10.1093/infdis/jiab361. - DOI - PMC - PubMed
    1. Abdelnabi R., Foo C.S., Kaptein S.J.F., Zhang X., Do T.N.D., Langendries L., Vangeel L., Breuer J., Pang J., Williams R., Vergote V., Heylen E., Leyssen P., Dallmeier K., Coelmont L., Chatterjee A.K., Mols R., Augustijns P., De Jonghe S., Jochmans D., Weynand B., Neyts J. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. eBioMedicine. 2021;72:103595. - PMC - PubMed
    1. Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., Natchus M.G., Saindane M., Kolykhalov A.A., Painter G.R., Baric R.S., Denison M.R. Small-molecule antiviral β-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93 doi: 10.1128/JVI.01348-19. - DOI - PMC - PubMed
    1. Bojkova D., Widera M., Ciesek S., Wass M.N., Michaelis M., Cinatl J. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32(3):319–321. doi: 10.1038/s41422-022-00619-9. - DOI - PMC - PubMed
    1. Bullard, J., Dust, K., Funk, D., Strong, J., Alexander, D., Garnett, L., C, B., A, B., A, H., Z, S., K, D., N, B., Y, L., PG, V.C., G, P., 2020. predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin. Infect. Dis. 71, 2663–2666. <https://doi.org/10.1093/CID/CIAA638>. - PMC - PubMed

LinkOut - more resources